论文部分内容阅读
目的 :体外诱导肿瘤特异性细胞毒T淋巴细胞 (CTL) ,评价其抗肿瘤临床应用价值.方法 :采集患者外周血 ,分离淋巴细胞 ;手术切除肿瘤或转移淋巴结 ,分离肿瘤细胞 ;将淋巴细胞用肿瘤细胞体外致敏 ,诱导产生CTL细胞 ,并以rIL -2大量扩增后回输患者 ,观察其抗肿瘤作用及其对患者免疫功能的影响、并随访患者术后复发及生存期.对部分有转移病灶的病例应用单光子发射计算机断层仪 (ECT)进行5 1 Cr标志的CTL体内分布显像.结果 :CTL细胞过继性免疫治疗后 ,产生明显的抗肿瘤作用、增强患者的T细胞免疫功能、对于预防术后复发和转移具有明显作用.5 1 Cr标志的CTL体内分布显示 ,转移病灶处放射性浓聚.结论 :对于恶性肿瘤患者的综合治疗 ,CTL过继性免疫治疗是有效方法之一.“,”Objective:To induce cytotoxic T lymphocytes (CTL) specific for carcinoma and evaluate the effect of treatment with CTL . Methods: Interleukin-2 (IL-2) was added during the stimulation of peripheral blood lymphocytes with autologous tumor cells to generate tumor-specific CTL . CTL were transferred to the patients with carcinoma and their anti-tumor effects were observed . CTL labelled by using 51 Cr imaging was performed on three cases with metastatic lesions. Results:Adoptive CTL treatment could actirate effective anti-tumor immunity and delay significantly tumor recurrence and metastasis.A high tracer uptake was detected in metastatic lesions on imaging .Conclusions: Adoptive immunotherapy with CTL is one of the efficacious methods in the treatment of carcinoma .